NYSE:TARO - IL0010827181 - Common Stock
Taking everything into account, TARO scores 5 out of 10 in our fundamental rating. TARO was compared to 193 industry peers in the Pharmaceuticals industry. TARO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TARO has a valuation in line with the averages, but it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 2.49% | ||
ROE | 3% | ||
ROIC | 0.79% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 3.42% | ||
PM (TTM) | 8.55% | ||
GM | 48.47% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.61 | ||
Quick Ratio | 3.04 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 24.98 | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 22.96 | ||
EV/EBITDA | 5.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
42.97
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 24.98 | ||
Fwd PE | N/A | ||
P/S | 2.57 | ||
P/FCF | 22.96 | ||
P/OCF | 12.96 | ||
P/B | 0.9 | ||
P/tB | 0.91 | ||
EV/EBITDA | 5.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 2.49% | ||
ROE | 3% | ||
ROCE | 1.19% | ||
ROIC | 0.79% | ||
ROICexc | 1.53% | ||
ROICexgc | 1.56% | ||
OM | 3.42% | ||
PM (TTM) | 8.55% | ||
GM | 48.47% | ||
FCFM | 11.18% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 174.37% | ||
Cap/Sales | 8.62% | ||
Interest Coverage | 250 | ||
Cash Conversion | 236.87% | ||
Profit Quality | 130.77% | ||
Current Ratio | 3.61 | ||
Quick Ratio | 3.04 | ||
Altman-Z | N/A |